MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

SOLV · NYSE

Solventum Corporation

Health Care · Medical/Dental Instruments

Reference price$86.17As of Jul 28, 2026
Market capitalization$14.92B
52-week range$62.38–$88.20
S&P 500 portfolio weight0.02%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$66.00-23.4% vs. reference
Average$84.89-1.5% vs. reference
High$95.00+10.2% vs. reference
6 Buy3 Hold1 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportAug 5, 2026Jun 2026
Consensus EPS$1.915 estimates
Expected range$1.85–$1.95Low to high EPS
Dec 2026$6.58Street EPS consensus
Dec 2027$7.10Street EPS consensus
Dec 2028$7.91Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+0.9% YoY$8.33B$8.25B
Operating income$2.18B$1.04B
Net income$1.56B$0.48B
Operating cash flow$0.37B$1.19B
Capital expenditures($0.38B)($0.38B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

Why Solventum (SOLV) is a Top Stock for the Long-Term

Zacks

Earnings Growth & Price Strength Make Solventum (SOLV) a Stock to Watch

Zacks

Why Solventum (SOLV) is a Top Stock for the Long-Term

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.